PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.42
Negative P/E while RVPH shows 24.57. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
3.78
P/B 50-75% of RVPH's 5.39. Bruce Berkowitz would examine if asset composition explains the gap.
-6.71
Negative FCF while RVPH shows P/FCF of 98.29. Joel Greenblatt would examine cash flow improvement potential.
-6.71
Negative operating cash flow while RVPH shows P/OCF of 98.29. Joel Greenblatt would examine operational improvement potential.
3.78
Fair value ratio 50-75% of RVPH's 5.39. Bruce Berkowitz would examine if business quality explains the gap.
-17.57%
Negative earnings while RVPH shows yield of 1.02%. Joel Greenblatt would examine path to profitability.
-14.90%
Negative FCF while RVPH shows yield of 1.02%. Joel Greenblatt would examine cash flow improvement potential.